Phospholipids pp 123-132 | Cite as

Biological Behaviour of Liposomes

  • Gregory Gregoriadis


Many drugs in therapeutic, diagnostic and preventive medicine would be more effective if they were to act selectively, where they are needed (4). Barring a few exceptions (e.g. antibiotics interfering with metabolic pathways in bacteria), however, drug selectivity is often poor. For example, in cancer chemotherapy cytostatic agents also damage normal rapidly proliferating cells. Additional obstacles to effective drug action include inaccessibility of targets (e.g. many antimicrobial agents are unable to reach microbe-infested intracellular sites), drug instability in the biological milieu, premature drug loss through excretion and allergic reactions to some drugs.


Tetanus Toxoid Lysosomal Storage Disease Positive Surface Charge Muramyl Dipeptide Liposomal Drug 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bangham, A.D., Hill, M.W., and Miller, N.G.A., 1974, Preparation and use of liposomes as models of biological membranes, Meth. Membr. Biol. 1:1–68.CrossRefGoogle Scholar
  2. 2.
    Chiang, C.M., and Weiner, N., 1987, Gastrointestinal uptake of liposomes: In vivo studies, Int. J. Pharmaceutics 40:143–150.CrossRefGoogle Scholar
  3. 3.
    Davis, D., and Gregoriadis, G., 1987, Liposomes as adjuvants with immunopurified tetanus toxoid: Influence of liposomal characteristics, Immunology, 61:229–234.PubMedGoogle Scholar
  4. 4.
    de Duve, C., 1979, Forward in: “Drug Carriers in Biology and Medicine,” G. Gregoriadis, ed., Academic Press, London, pp. IX–XI.Google Scholar
  5. 5.
    Gabizon, A., and Papahad jopoulus, D., 1988, Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumours, Proc. Nat. Acad. Sci., USA, 85:6949–6953.CrossRefGoogle Scholar
  6. 6.
    Garcon, N., Gregoriadis, G., Taylor, M., and Summerfield, J., 1988, Targeted immunoadjuvant action of tetanus toxoid-containing liposomes coated with mannosylated albumin, Immunology, 64:743–745.PubMedGoogle Scholar
  7. 7.
    Gregoriadis, G., 1983, Targeting of Drugs with molecules, cells and liposomes, Trends Pharm Sci., 4:304–307.CrossRefGoogle Scholar
  8. 8.
    Gregoriadis, G. (ed.), 1984, “Liposome Technology”, vols 1–3, CRC Press Inc., Boca Raton.Google Scholar
  9. 9.
    Gregoriadis, G. (ed.), 1988, “Liposomes as Drug Carriers: Recent Trends and Progress”, Wiley, Chichester.Google Scholar
  10. 10.
    Gregoriadis, G., 1990, Immunological adjuvants: A role for liposomes, Immunology Today, 11:89–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Gregoriadis, G., Neerunjun, D.E., Meade, T.W., and Bull, G.M., 1980, Experiences after long-term treatment of an adult Gaucher’s disease patient with liposomal glucocerebroside:β-glucosidase in: “Enzyme Therapy in Genetic Diseases,” by J. Desnick, Ed., Alan R. Liss Inc., New York, pp. 383–392.Google Scholar
  12. 12.
    Lopez-Berestein, G., and Fidler, I. (eds.), 1989, “Liposomes in the Therapy of Infectious Diseases and Cancer”, Alan R. Liss, Inc., New York.Google Scholar
  13. 13.
    Rahman, Y.E., Rosenthal, M.W., and Cerny, E.A., 1973, Intracellular plutonium removal by liposomeencapsulated chelating agent, Science, 180:300–302.PubMedCrossRefGoogle Scholar
  14. 14.
    Sells, R.A., Gilmore, I.T., Owen, R.E., New, R.R.C., and Stringer, R.E., 1987, Reduction in doxorubicin toxicity following liposomal delivery, Cancer Treatment Reports, 14:383–387.CrossRefGoogle Scholar
  15. 15.
    Tan, L., and Gregoriadis, G., 1989, The effect of positive surface charge of liposomes on their clearance from blood and its relation to vesicle lipid composition Biochem. Soc. Trans., 17:690–691.Google Scholar
  16. 16.
    Tan, L., and Gregoriadis, G., 1989, The effect of interleukin-2 on the immunoadjuvant action of liposomes, Biochem. Soc. Trans., 17:693–694.Google Scholar
  17. 17.
    Wolff, B., and Gregoriadis, G., 1984, The use of monoclonal antibody Thy1 IgG1 for the targeting of liposomes to AKR-A cells in vitro and in vivo, Biochem. Biophys. Acta., 802:259–273.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Gregory Gregoriadis
    • 1
  1. 1.Centre for Drug Delivery Research The School of PharmacyUniversity of LondonLondonUK

Personalised recommendations